Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of Sestamibi SPECT/CT.
A Tzortzakakis - 2017 - Soc Nuclear Med
751 Objectives: Despite the progress in the quality of multiphasic CT and MRI scans, it is still
difficult to fully characterize a solid kidney lesion. Approximately 10% of all solid renal …
difficult to fully characterize a solid kidney lesion. Approximately 10% of all solid renal …
[HTML][HTML] Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of 99mTc-sestamibi SPECT/CT
A Tzortzakakis, O Gustafsson, M Karlsson… - EJNMMI research, 2017 - Springer
Background Despite the progress in the quality of multiphasic CT and MRI scans, it is still
difficult to fully characterize a solid kidney lesion. Approximately 10% of all solid renal …
difficult to fully characterize a solid kidney lesion. Approximately 10% of all solid renal …
Sestamibi quantitative evaluation of renal masses
T Standiford, S Bell, R Wang, A Kutikov, J Schober… - 2023 - Soc Nuclear Med
P984 Introduction: The differentiation of renal cell carcinoma (RCC) from oncocytoma is
challenging with the current imaging techniques. By result, resection has traditionally been …
challenging with the current imaging techniques. By result, resection has traditionally been …
[PDF][PDF] Protocol for a MULTI-centre feasibility study to assess the use of 99m Tc-sestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study)
N Campain, R Devon, NHS Exeter - 2022 - scienceopen.com
The incidence of renal tumours is increasing and anatomic imaging cannot reliably
distinguish benign tumours from renal cell carcinoma (RCC). Up to 30% of renal tumours are …
distinguish benign tumours from renal cell carcinoma (RCC). Up to 30% of renal tumours are …
[HTML][HTML] Protocol: Protocol for a MULTI-centre feasibility study to assess the use of 99mTc-sestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study)
Introduction The incidence of renal tumours is increasing and anatomic imaging cannot
reliably distinguish benign tumours from renal cell carcinoma. Up to 30% of renal tumours …
reliably distinguish benign tumours from renal cell carcinoma. Up to 30% of renal tumours …
Protocol for a MULTI-centre feasibility study to assess the use of 99mTc-sestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study)
Introduction The incidence of renal tumours is increasing and anatomic imaging cannot
reliably distinguish benign tumours from renal cell carcinoma. Up to 30% of renal tumours …
reliably distinguish benign tumours from renal cell carcinoma. Up to 30% of renal tumours …
99mTc-Sestamibi SPECT/CT and histopathological features of oncocytic renal neoplasia
A Tzortzakakis, T Papathomas… - … Journal of Urology, 2022 - Taylor & Francis
Abstract Background 99mTc-Sestamibi Single Photon Emission Computed Tomography/
Computed Tomography (SPECT/CT) contributes to the non-invasive differentiation of renal …
Computed Tomography (SPECT/CT) contributes to the non-invasive differentiation of renal …
Diagnostic accuracy of 99mTc-Sestamibi SPECT/CT for characterization of solid renal masses
AS Parihar, J Mhlanga, C Ronstrom… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Our objective was to assess the diagnostic accuracy of 99mTc-sestamibi SPECT/CT for
characterizing solid renal masses. Methods: Imaging and clinical records of patients who …
characterizing solid renal masses. Methods: Imaging and clinical records of patients who …
Differentiation of renal oncocytoma from renal cell carcinoma by means of ⁹⁹Tc-Sestamibi SPECT/CT
A Tzortzakakis - 2021 - openarchive.ki.se
Purpose: An increasing body of literature indicates the beneficial role of [99m] Tc-Sestamibi
SPECT/CT in the non-invasive differentiation of renal oncocytoma (RO) from renal cell …
SPECT/CT in the non-invasive differentiation of renal oncocytoma (RO) from renal cell …
Application of Quantitative SPECT-CT reconstructions with 99mTc-sestamibi renal imaging of patients with cT1 renal masses.
745 Objectives: CT and MRI are unable to reliably distinguish between benign and
malignant renal tumors, with approximately 15-20% of resected lesions resulting in a benign …
malignant renal tumors, with approximately 15-20% of resected lesions resulting in a benign …